

* HEMLIBRA INJECTION TIPS AND TRICKS GUIDE *

This quick guide walks you through **community-sourced**, **helpful injection tips**, with the goal of making HEMLIBRA a comfortable injection experience.

Before injecting HEMLIBRA, it's important that you read, understand, and follow the <u>Instructions for Use</u>. Remember that you should not attempt to inject your child with HEMLIBRA until you've received training from your doctor.

INDICATION & IMPORTANT SAFETY INFORMATION

What is **HEMLIBRA**?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:

- Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
- Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head

Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.



TIP 1. Allow Hemlibra to warm to room temperature

Take the HEMLIBRA vial out of the refrigerator and allow it to reach room temperature before use. Giving HEMLIBRA enough time to warm up may help make the injection more comfortable.

- For example, if you plan to inject first thing in the morning, you could get into a routine of taking the vial out of the refrigerator the night before
- HEMLIBRA should not be stored out of the refrigerator for more than a total of 7 days or at a temperature greater than 86°F (30°C)

TIP 2. Make your child a part of the injection process

You know your child best, so communicate with them in a manner that gives them some sense of control and empowerment over the experience in a way that's safe and age appropriate.

- Whether it's comforting words or rewarding their behavior, find a routine that makes each injection seamless and predictable
- For example, older children could help by getting cotton balls, washing their hands, or locating the adhesive bandage strips. This can help them feel empowered and focused on having a job





TIP 3. HELP YOUR CHILD FIND AN INJECTION SITE THAT FEELS BEST FOR THEM

Find an injection site that's most comfortable for your child. Injection sites include: the thigh (front and middle), the stomach area or abdomen (except for 2 inches around the belly button), and the outer area of the upper arm (only if a caregiver is giving the injection). For example, Maria—a HEMLIBRA caregiver ambassador—says her son, Carlos, prefers that she administer his injection in the outer area of the upper arm. Once you find an area that works for your child, you can continue injecting there—just make sure you rotate sites by at least 1 inch each time you inject.

INDICATION & IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about HEMLIBRA? (cont'd)

Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.



TIP 4. KEEP YOUR CHILD ENGAGED WITH A FUN DISTRACTION

A fun distraction, like their favorite book, game, or TV show may help reduce your child's stress and keep them at ease during the injection.

TIP 5. INSERT THE NEEDLE ANYWHERE BETWEEN A 45° AND 90° ANGLE, AND THEN INJECT SLOWLY

Injections must be given anywhere between a 45° and 90° angle. Work with your doctor to find an angle that feels best for your child.

Insert the needle quickly and firmly, then slowly press the plunger down while injecting. Slowly pressing the plunger may help make the experience more comfortable.





TIP 6. REMEMBER THAT HEMLIBRA HAS FLEXIBLE DOSING OPTIONS

Children are always growing and changing, so talk to your doctor about changing your child's dosage and dosing schedule so it continues to fit their needs as they get older.

Remember that HEMLIBRA provides flexible dosing options,* and having a dosing regimen that works for your child can help improve the treatment experience.

*After the first 4 weekly loading doses, HEMLIBRA can be taken once a week, once every 2 weeks, or once every 4 weeks.

INDICATION & IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about HEMLIBRA? (cont'd)

Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).



Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.

CLICK HERE

For more information on injecting HEMLIBRA, including the Instructions for Use and a step-by-step injection video.

WE ARE LISTENING

Whether you feel confident in your approach to injections or if you're still learning, Account & Community Managers (ACMs) are here and available for you.

Reach out for 1:1 support or to share how these tips worked for you and your loved one. Your lived experience is important to us and the hemophilia A community.

ACMs are Genentech employees and do not provide medical advice. Always talk to your doctor about treatment options.

TRUSTED BY THE COMMUNITY FOR 7 YEARS AND COUNTING

FIRST APPROVED IN 2017* | OVER 25,000 PEOPLE WORLDWIDE[†] AND OVER 8,500 PEOPLE IN THE US TREATED WITH HEMLIBRA[‡]

*November 2017: FDA approval for adults and children with hemophilia A with factor VIII inhibitors. *Number of people with hemophilia A treated with HEMLIBRA worldwide as of April 2024. *Number of people with hemophilia A treated with HEMLIBRA in the US as of February 2025.

INDICATION & IMPORTANT SAFETY INFORMATION

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:

- Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
- Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head

Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.

Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).

The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

What else should I know about HEMLIBRA?

See the detailed "Instructions for Use" that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

- Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
- You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.

These are not all of the possible side effects of HEMLIBRA. Speak to your healthcare provider for medical advice about side effects.

Side effects may be reported to the FDA at (800) FDA-1088 or <u>www.fda.gov/medwatch</u>. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. The HEMLIBRA logo is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.

The Genentech logo is a registered trademark of Genentech, Inc.

All other trademarks are the property of their respective owners.

©2025 Genentech USA, Inc. All rights reserved. M-US-00027038(v1.0) 04/25

